The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 23.00
Bid: 22.00
Ask: 24.00
Change: 0.00 (0.00%)
Spread: 2.00 (9.091%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 23.00
CKT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options and PDMR dealings

29 Mar 2022 07:00

RNS Number : 2988G
Checkit PLC
29 March 2022
 

Checkit plc 

("Checkit" or the "Group")

Grant of options and PDMR dealings

Checkit plc (AIM: CKT) announces that, on 25 March 2022, it granted options over ordinary shares of 5 pence each ("Ordinary Shares") to Kit Kyte, Chief Executive Officer, under the Checkit plc 2020 Enterprise Management Incentive Plan (the "Plan").

This grant of options and the terms of the Plan, were determined by Checkit's Remuneration Committee following consultation with the Group's significant shareholders.

Under the terms of the Plan, Mr. Kyte has been granted nominal cost options over 1,500,000 Ordinary Shares. The options will vest over three separate periods in tranches of 500,000 options. The vesting date for the first tranche of options will be 10 business days after the publication of the Group's audited annual accounts for the financial year ending 31 January 2025 or, in the Board's absolute discretion, 10 business days after the publication of the Group's interim report for the financial year ending 31 January 2026. The vesting date for the second tranche shall follow the same pattern as the first tranche albeit for the financial year ending 31 January 2026 in relation to the audited annual accounts and 31 January 2027 for the interim report. The vesting date for the third tranche shall be the date 10 business days from the publication of the audited consolidated accounts for the Group for the financial year ending 31 January 2027.

Each tranche of options will be subject to performance criteria and shall only vest subject to a 'Rule of 40 Target' being met on the dates outlined above. In addition, to be exercisable, the share price must be at or above a share price target of 130p (the "Share Price Target") on the date the options are exercised and the average share price must have been at or above this level during the 6 months prior to the exercise date.

The Rule of 40 Target will be calculated as follows:

ARR Growth % + L/EBITDA Margin %

· The ARR Growth % is measured by calculating the percentage growth in Annual Recurring Revenue (ARR) compared with the previous year.

· The L/EBITDA Margin % is measured in each year by calculating the earnings or losses of the Group as a percentage of its revenue, before interest, tax, depreciation and amortisation and before costs in relation to share incentive plans, but after deduction of all spending on NPD and cash based exceptional items as determined by the Board.

 

The Rule of 40 is used commonly in SaaS companies to measure performance by reference to both profits and growth.

The full number of options granted will not be exercisable until after a minimum vesting period has passed of over five years from the grant date. Subject to the Rule of 40 vesting requirements, the Share Price Target must be achieved within just over six years of grant in order for the options to become exercisable, enabling a full six years of Kit Kyte's performance as Chief Executive Officer to be measured.

In the event of a change of control event, the Rule of 40 Target will be determined by reference to the Group's latest annual or interim report and the Share Price Target will be met if the price paid by a person obtaining control of the Group exceeds 130 pence per Ordinary Share.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

Enquiries:

Checkit plc

 

+44 (0)1223 643313

www.checkit.net

 

 

John Wilson (Non-Executive Director, Chairman of Remuneration Committee)

 

 

Kit Kyte (Chief Executive Officer)

 

 

Greg Price (Chief Financial Officer)

 

 

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Shaun Dobson / Harry Gooden / George Tzimas (Investment Banking)

 

 

 

 

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name:

Kit Kyte

 

2

Reason for the notification

 

a)

Position/Status:

 

Chief Executive Officer (PDMR)

b)

Initial Notification/Amendment:

 

Initial Notification

3

Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor

 

a)

Name:

Checkit Plc

 

b)

LEI:

213800556WJOWQNT2R68 

4.

Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.

 

a)

Description of the financial instrument:

Identification code:

Ordinary Shares of 5 pence each

ISIN GB00B0C5RG72

b)

Nature of the transaction:

 

Grant of options over Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

 

Exercisable at 5 pence per Ordinary Share

Volume(s)

 

1,500,000

d)

Aggregated information

- Aggregated volume

 

- Price

 

N/A single transaction

e)

Date of the Transaction:

 

25 March 2022

 

f)

Place of the Transaction:

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHQVLFLLXLLBBZ
Date   Source Headline
29th Apr 20242:59 pmRNSDirector/PDMR Shareholding
25th Apr 20247:00 amRNSFinal Results
17th Apr 20242:35 pmRNSNotice of Results and Investor Presentation
15th Apr 20247:00 amRNSNew Product Launch and Contract Wins
14th Mar 20248:49 amRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSGrant of Options and PDMR Dealings
8th Mar 20249:00 amRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSInvestor Presentation
1st Feb 20242:25 pmRNSSurrender of Existing Options
7th Nov 20237:00 amRNSDirector/PDMR Shareholding
14th Sep 20237:00 amRNSInterim Results
24th Aug 20237:00 amRNSInvestor Presentation
10th Aug 20237:00 amRNSTrading update notice of results & contract
8th Jun 20234:08 pmRNSResult of AGM
24th May 20233:29 pmRNSDirector/PDMR Shareholding
15th May 20231:04 pmRNSPosting of Annual Report and Notice of AGM
24th Apr 20237:00 amRNSPreliminary Results
13th Apr 20231:36 pmRNSNotice of Results and Investor Presentation
23rd Mar 20235:25 pmRNSDirector/PDMR Shareholding
13th Mar 20238:55 amRNSStatement re. Silicon Valley Bank
16th Feb 20237:00 amRNSTrading Update and Notice of Results
26th Jan 20234:10 pmRNSDirectorate Change
23rd Jan 20237:00 amRNSDirector/PCA Dealing
10th Jan 20237:00 amRNSAppointment of Non-Executive Director
10th Jan 20237:00 amRNSGrant of options and PDMR dealings
5th Jan 20237:00 amRNSContract wins and investor presentation
12th Dec 20225:14 pmRNSDirector/PDMR Shareholding
27th Sep 202212:28 pmRNSHolding(s) in Company
23rd Sep 20226:16 pmRNSDirector/PDMR Shareholding
16th Sep 20225:36 pmRNSDirector Dealing
15th Sep 20227:00 amRNSInterim Results
6th Sep 20227:00 amRNSInvestor Presentation
22nd Aug 20221:07 pmRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSTrading Update and Notice of Interim Results
9th Jun 20223:09 pmRNSResult of AGM
13th May 20225:17 pmRNSPosting of Annual Report and Notice of AGM
13th May 20227:00 amRNSInvestor Conference
4th May 20227:00 amRNSContract Renewal
28th Apr 20227:00 amRNSPreliminary Results
29th Mar 20227:00 amRNSGrant of options and PDMR dealings
23rd Feb 20227:00 amRNSPDMR Dealing
22nd Feb 20227:00 amRNSPDMR Dealing
17th Feb 20227:00 amRNSTrading update
1st Feb 20227:00 amRNSContract win
22nd Dec 20212:06 pmRNSHolding(s) in Company
20th Dec 20217:01 amEQSCheckit (CKT): SaaS software for the deskless workforce
17th Dec 20212:44 pmRNSDirector/PDMR Shareholding
16th Dec 202111:52 amRNSResult of General Meeting and Admission
2nd Dec 202111:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.